Exact Sciences Corporation
EXAS
Rankning i aktier
#1157
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Aktiekurs
$104.91
Senast synkroniserad: 2026-03-23
Marknadsvärde
$20.03B
Förändring (1 dag)
0.00%
Förändring (1 år)
65.45%
Land
US
Handel Exact Sciences Corporation (EXAS)
Kategori
Healthcare
Antal utestående aktier för Exact Sciences Corporation (EXAS)
Antal utestående aktier per December 2025: 189.74M
Enligt de senaste finansiella rapporterna och aktiekursen för Exact Sciences Corporation är det aktuella antalet utestående aktier 189.74M. I slutet av December 2024 hade företaget 184.20M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Exact Sciences Corporation (EXAS) från 2000 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 189.74M | 0.56% |
| 2025 | 188.69M | 2.44% |
| 2024 | 184.20M | 2.25% |
| 2023 | 180.14M | 2.15% |
| 2022 | 176.35M | 2.92% |
| 2021 | 171.35M | 13.37% |
| 2020 | 151.14M | 15.15% |
| 2019 | 131.26M | 7.41% |
| 2018 | 122.21M | 5.64% |
| 2017 | 115.68M | 13.04% |
| 2016 | 102.34M | 11.07% |
| 2015 | 92.14M | 14.84% |
| 2014 | 80.23M | 18.87% |
| 2013 | 67.49M | 13.47% |
| 2012 | 59.48M | 13.27% |
| 2011 | 52.51M | 29.80% |
| 2010 | 40.46M | 23.37% |
| 2009 | 32.79M | 20.50% |
| 2008 | 27.21M | 0.99% |
| 2007 | 26.95M | 1.64% |
| 2006 | 26.51M | 0.91% |
| 2005 | 26.27M | 3.69% |
| 2004 | 25.33M | 33.96% |
| 2003 | 18.91M | 2.59% |
| 2002 | 18.43M | 11.80% |
| 2001 | 16.49M | 1,027.91% |
| 2000 | 1.46M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 371.00M | 95.53% |
US
|
|
| 705.30M | 271.72% |
US
|
|
| 143.28M | -24.49% |
US
|
|
| - | - |
CN
|
|
| 282.00M | 48.63% |
US
|
